Clinical Trials Logo

Smoldering Multiple Myeloma clinical trials

View clinical trials related to Smoldering Multiple Myeloma.

Filter by:

NCT ID: NCT03952832 Not yet recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma

Start date: June 11, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well leflunomide works in treating patients with high-risk smoldering multiple myeloma. Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03951220 Recruiting - Myeloma Clinical Trials

The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss

LOOMIS
Start date: March 29, 2018
Phase:
Study type: Observational

In the proposed study, the investigators will aim to develop and pilot a Magnetic Resonance (MR) imaging protocol and assess its ability to achieve the following: quantification of tumour burden and bone loss, detecting longitudinal changes in tumour load with therapy and detecting longitudinal changes in microarchitecture with therapy. The investigators also aim to investigate whether bone loss is better, worse or the same with different imaging techniques. This will be investigated by correlating the DXA imaging data with Diffusion-Weighted Magnetic Resonance Imaging (DWMRI) to see if it is possible to achieve quantifiable data of bone density.

NCT ID: NCT03937635 Recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Start date: April 30, 2019
Phase: Phase 3
Study type: Interventional

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.

NCT ID: NCT03850522 Recruiting - Clinical trials for Smoldering Multiple Myeloma

Phase IIa Trial of PD-L1 Peptide Vaccination as Monotherapy in High Risk Smoldering Multiple Myeloma

Start date: February 18, 2019
Phase: Phase 2
Study type: Interventional

This study is evaluating a new vaccine against PD-L1 as a possible treatment for high-risk smoldering multiple myeloma.

NCT ID: NCT03839459 Recruiting - Clinical trials for Smoldering Multiple Myeloma

Denosumab for Smoldering Multiple Myeloma

Start date: April 19, 2019
Phase: Phase 2
Study type: Interventional

This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.

NCT ID: NCT03815279 Not yet recruiting - Multiple Myeloma Clinical Trials

A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)

iStopMM
Start date: May 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy of treating patients with intermediate risk smoldering multiple myeloma (SMM) with combinational therapy with dexamethasone and lenalidomide (Rd) and patients with high risk SMM with combinational therapy with Rd and carfilzomib.

NCT ID: NCT03717844 Recruiting - Multiple Myeloma Clinical Trials

Registry for Adults With Plasma Cell Disorders (PCD's)

Start date: February 9, 2018
Phase:
Study type: Observational [Patient Registry]

The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric assessment," as is outlined in this protocol. Secondary objectives include measuring the response rate to participation of patients in this study, assessing patient satisfaction with the questionnaire, and gathering information that would lend support for future research into these types of assessments in patients with PCDs. Additionally the study offers an optional blood draw to look at a genetic marker of aging called p16INK4a (IRB 15-1899, IRB 15-0244).

NCT ID: NCT03657251 Not yet recruiting - Multiple Myeloma Clinical Trials

MMRF CureCloud Research Initiative

Start date: June 15, 2019
Phase:
Study type: Observational [Patient Registry]

The MMRF CureCloud Research Initiative, a Direct-to-Patient Research effort aimed at enrolling 5,000 individuals from whom comprehensive molecular and immune analyses will be generated from blood specimens and the resulting data aggregated with the correlating clinical information. Blood will be collected from all participants after electronic online consenting via a mailed blood kit designed for a mobile phlebotomy appointment. Through the consenting process, participants will also be authorizing linkage to their electronic medical records information.

NCT ID: NCT03631043 Active, not recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Personalized Vaccine in Treating Participants With Smoldering Multiple Myeloma

Start date: December 21, 2018
Phase: Early Phase 1
Study type: Interventional

This early phase I trial studies the side effects of personalized vaccine in treating participants with smoldering multiple myeloma. Vaccines made from a person's blood and bone marrow may help the body build an effective immune response to kill cancer cells.

NCT ID: NCT03591614 Not yet recruiting - Myeloma Clinical Trials

Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma

Start date: June 2019
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to study the safety and preliminary efficacy of a dendritic cell DKK1 vaccine against myeloma. Dendritic cells are immune cells that are collected from the blood of the patient at Case Western Reserve Medical Center and then brought into contact with DKK1, a molecule that is present of myeloma cells but not to a significant amount on other cells except for the prostate and the placenta. It is an investigational (experimental) vaccine that based on studies in the laboratory and in mice is expected to work by presentation of DKK1 to anticancer immune cells via dendritic cells leading to an immune attack on myeloma cells. It is experimental because it is not approved by the Food and Drug Administration (FDA).